Glomerular Filtration Rate (eGFR) & CKD-EPI Calculator
Calculate renal filtration function using the 2021 race-free CKD-EPI equation, Cockcroft-Gault creatinine clearance (CrCl) for drug dosing, MDRD formula, and KDIGO chronic kidney disease risk staging.
Glomerular Filtration Rate (eGFR) & CKD-EPI Calculator: Free Glomerular Filtration Rate (eGFR) & CKD-EPI Calculator tool: calculate estimated GFR using the 2021 race-free CKD-EPI equation, Cockcroft-Gault.
Patient Clinical Parameters
Renal Filtration Results
Clinical Nephrology: Mechanics and Formulas for Renal Function Estimation
The Glomerular Filtration Rate (GFR) represents the cumulative volume of ultrafiltrate formed across the microscopic glomerular capillaries of both kidneys per unit time. Under normal physiological conditions in a healthy young adult, approximately $120 ext{ to } 130 ext{ mL/min}$ ($180 ext{ L/day}$) of fluid is filtered from renal blood flow into Bowman's capsule. Because direct clearance measurements utilizing exogenous filtration markers such as inulin infusion or radiolabeled iohexol are invasive, labor-intensive, and prohibitively expensive for routine practice, clinical medicine relies upon continuous estimating equations derived from endogenous biomarkers—predominantly serum creatinine.
Starling Forces Governing Glomerular Ultrafiltration
Fluid flux across the fenestrated glomerular capillary wall conforms strictly to the classical Starling equation of microvascular exchange:
where $K_f$ is the ultrafiltration coefficient (the product of capillary surface area and hydraulic permeability), $P_{ ext{gc}}$ is glomerular capillary hydrostatic pressure (~$50 ext{ mmHg}$), $P_{ ext{bs}}$ is Bowman's space hydrostatic pressure (~$10 ext{ mmHg}$), $pi_{ ext{gc}}$ is glomerular capillary oncotic pressure (~$25 ext{ to } 35 ext{ mmHg}$), and $pi_{ ext{bs}}$ is Bowman's space oncotic pressure (effectively $0 ext{ mmHg}$ in the absence of severe proteinuria).
The 2021 Race-Free CKD-EPI Creatinine Equation
For over a decade, international guidelines utilized the 2009 CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula, which incorporated a race coefficient of $1.159$ for Black individuals under the historical assumption of higher average muscle mass. In 2021, an expert task force convened by the National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) published the refined 2021 Race-Free CKD-EPI Equation in the New England Journal of Medicine (Inker et al., 2021). The equation refits the epidemiological cohort data without any race multiplier, eliminating racial disparities in renal diagnosis, nephrology referral thresholds, and kidney transplantation listing.
Hyperparameters by biological sex:
- Females: $kappa = 0.7 ext{ mg/dL}$ ($61.9 ext{ }mu ext{mol/L}$), $alpha = -0.241$
- Males: $kappa = 0.9 ext{ mg/dL}$ ($79.6 ext{ }mu ext{mol/L}$), $alpha = -0.302$
The output is normalized to a standardized human body surface area of $1.73 ext{ m}^2$ ($ ext{mL/min/1.73 m}^2$).
The Cockcroft-Gault Creatinine Clearance Equation
Formulated in 1976 by Donald William Cockcroft and M. Henry Gault, this historic formula estimates total creatinine clearance ($ ext{CrCl}$) in absolute $ ext{mL/min}$:
Why Cockcroft-Gault Remains Essential: Virtually all pharmacokinetic trials conducted prior to 2010 established renal dosing cutoffs (such as for direct oral anticoagulants, vancomycin, aminoglycosides, and low molecular weight heparins) using Cockcroft-Gault CrCl. For obese patients ($ ext{BMI} ge 30 ext{ kg/m}^2$), using actual total body weight overestimates clearance, so clinical pharmacologists substitute Ideal Body Weight (IBW) or Adjusted Body Weight (ABW): $$ ext{IBW}_{ ext{Male}} = 50 ext{ kg} + 2.3 imes ( ext{Height in inches} - 60)$$ $$ ext{IBW}_{ ext{Female}} = 45.5 ext{ kg} + 2.3 imes ( ext{Height in inches} - 60)$$ $$ ext{ABW} = ext{IBW} + 0.4 imes ( ext{Actual Weight} - ext{IBW})$$
The Modification of Diet in Renal Disease (MDRD) Study Equation
Introduced by Levey et al. in 1999 (revised to 4 variables with IDMS traceable creatinine in 2006): $$ ext{eGFR}_{ ext{MDRD}} = 175 imes (S_{ ext{cr}})^{-1.154} imes ( ext{Age})^{-0.203} imes [0.742 ext{ if Female}]$$ While MDRD performed well in patients with established moderate-to-severe renal disease, it systematically underestimated GFR in healthy individuals with GFR $> 60 ext{ mL/min/1.73 m}^2$, leading to significant false-positive CKD diagnoses. The 2021 CKD-EPI equation has formally superseded MDRD across modern clinical laboratories.
KDIGO 2024 CKD Classification and Prognosis Heatmap
Under the Kidney Disease: Improving Global Outcomes (KDIGO) consensus guidelines, chronic kidney disease is defined as abnormalities of kidney structure or function persisting for $> 3 ext{ months}$. Diagnosis requires combining the GFR category (G1–G5) with the urine Albumin-to-Creatinine Ratio (ACR category A1–A3):
| KDIGO Stage | eGFR Range (mL/min/1.73m²) | Clinical Description | A1 (ACR < 30 mg/g) | A2 (ACR 30–300 mg/g) | A3 (ACR > 300 mg/g) |
|---|---|---|---|---|---|
| G1 | ≥ 90 | Normal or High Function | Low Risk (Green) | Moderate Risk (Yellow) | High Risk (Orange) |
| G2 | 60 – 89 | Mildly Decreased | Low Risk (Green) | Moderate Risk (Yellow) | High Risk (Orange) |
| G3a | 45 – 59 | Mild-to-Moderately Decreased | Moderate Risk (Yellow) | High Risk (Orange) | Very High Risk (Red) |
| G3b | 30 – 44 | Moderate-to-Severely Decreased | High Risk (Orange) | Very High Risk (Red) | Very High Risk (Red) |
| G4 | 15 – 29 | Severely Decreased | Very High Risk (Red) | Very High Risk (Red) | Very High Risk (Red) |
| G5 | < 15 | Kidney Failure / ESRD | Very High Risk (Red) | Very High Risk (Red) | Very High Risk (Red) |
Step-by-Step Worked Numerical Examples
Example 1: Middle-Aged Male with Mild Renal Impairment
Patient: 55-year-old male, weight = 78 kg, height = 175 cm. Laboratory serum creatinine $S_{ ext{cr}} = 1.20 ext{ mg/dL}$ ($106.1 ext{ }mu ext{mol/L}$), urine albumin-to-creatinine ratio $ ext{ACR} = 15 ext{ mg/g}$ (Category A1).
Step 1: Compute 2021 Race-Free CKD-EPI eGFR:
For males: $kappa = 0.9$, $alpha = -0.302$. $$ rac{S_{ ext{cr}}}{kappa} = rac{1.20}{0.90} = 1.3333 > 1.0$$ $$minleft( rac{S_{ ext{cr}}}{kappa}, 1 ight) = 1.0 implies 1.0^{-0.302} = 1.0$$ $$maxleft( rac{S_{ ext{cr}}}{kappa}, 1 ight)^{-1.200} = (1.3333)^{-1.200} = 0.7071$$ $$ ext{Age factor: } 0.9938^{55} = 0.7101$$ $$ ext{eGFR} = 142 imes 1.0 imes 0.7071 imes 0.7101 = 142 imes 0.5021 = 71.3 ext{ mL/min/1.73 m}^2$$ KDIGO Stage: G2 (Mildly Decreased), Low Risk composite classification.Step 2: Compute Cockcroft-Gault CrCl for Drug Dosing:
$$ ext{CrCl} = rac{(140 - 55) imes 78}{72 imes 1.20} = rac{85 imes 78}{86.4} = rac{6630}{86.4} = 76.7 ext{ mL/min}$$Step 3: MDRD Comparison:
$$ ext{eGFR}_{ ext{MDRD}} = 175 imes (1.20)^{-1.154} imes (55)^{-0.203} = 175 imes 0.8101 imes 0.4431 = 62.8 ext{ mL/min/1.73 m}^2$$Example 2: Elderly Female Anticoagulant (DOAC) Dosing Evaluation
Scenario: A 72-year-old female weighing 54 kg presents for non-valvular atrial fibrillation anticoagulation. Serum creatinine is $1.35 ext{ mg/dL}$ ($119.3 ext{ }mu ext{mol/L}$).
1. CKD-EPI 2021:
With $kappa = 0.7$, $S_{ ext{cr}} / kappa = 1.35 / 0.7 = 1.9286$.
$$ ext{eGFR} = 142 imes (1.9286)^{-1.200} imes 0.9938^{72} imes 1.012 = 142 imes 0.4533 imes 0.6397 imes 1.012 = 41.7 ext{ mL/min/1.73 m}^2$$
Staged as G3b (Moderate-to-Severe CKD).
2. Cockcroft-Gault CrCl:
$$ ext{CrCl} = rac{(140 - 72) imes 54}{72 imes 1.35} imes 0.85 = rac{68 imes 54}{97.2} imes 0.85 = rac{3672}{97.2} imes 0.85 = 37.78 imes 0.85 = 32.1 ext{ mL/min}$$
Critical Clinical Discrepancy: Notice that Cockcroft-Gault clearance ($32.1 ext{ mL/min}$) is nearly $10 ext{ mL/min}$ lower than normalized eGFR ($41.7 ext{ mL/min/1.73 m}^2$) due to the patient's low body weight ($54 ext{ kg}$). Relying solely on eGFR would risk severe DOAC overdosing and fatal hemorrhage!
Comparative Analysis of Renal Biomarkers
| Biomarker / Method | Physiological Characteristics | Confounding Factors | Clinical Utility |
|---|---|---|---|
| Serum Creatinine | Breakdown of skeletal muscle creatine; filtered + 10-15% tubular secretion | Muscle mass, meat intake, amputations, cachexia, trimethoprim, cimetidine | Universal frontline screening and monitoring biomarker |
| Cystatin C | 13 kDa protein produced by all nucleated cells; freely filtered and reabsorbed | Thyroid disease, high-dose corticosteroids, smoking, severe obesity | Confirmatory test when creatinine is unreliable or discordant |
| 24-Hour Urine Creatinine | Direct collection to measure actual clearance $U cdot V / P$ | Incomplete collection (under/over collection errors), patient noncompliance | Pregnancy, extremes of body habitus, paraplegia, vegan diets |
| Inulin Clearance | Exogenous fructose polymer; ideal tracer (neither secreted nor reabsorbed) | Requires continuous IV infusion and catheterization; expensive | Gold-standard research reference method |
Clinical FAQs
Why does tubular secretion cause serum creatinine to overestimate true GFR?
In addition to glomerular ultrafiltration, approximately 10% to 15% of urinary creatinine is actively secreted into the urine via organic cation transporters (OCT2, MATE1) in the proximal convoluted tubule. Consequently, total creatinine excreted in urine exceeds filtered creatinine, causing creatinine clearance to overestimate true GFR. As renal disease progresses and GFR drops below $30 ext{ mL/min}$, tubular secretion accounts for an even larger proportion (up to 35%) of total elimination, exaggerating the overestimation of true GFR.
When should Cystatin C be ordered to confirm eGFR?
KDIGO guidelines recommend checking Cystatin C (calculating combined eGFRcr-cys) in patients whose creatinine-based eGFR is between $45 ext{ and } 59 ext{ mL/min/1.73 m}^2$ without albuminuria, to confirm or rule out true chronic kidney disease. It is also indicated in patients with atypical muscle mass (bodybuilders, amputees, muscular dystrophy, or neuromuscular paraplegia) where creatinine produces misleading values.
What is renal hyperfiltration and why is it dangerous?
Glomerular hyperfiltration (defined as eGFR $> 130 ext{ to } 140 ext{ mL/min/1.73 m}^2$) is an early pathological hallmark of diabetic nephropathy, obesity-related glomerulopathy, and high-protein intake. Elevated intraglomerular capillary hydrostatic pressure causes hemodynamic barotrauma and podocyte detachment, initiating progressive glomerulosclerosis that precedes overt kidney failure.
Frequently Asked Questions
In addition to glomerular ultrafiltration, approximately 10% to 15% of urinary creatinine is actively secreted into the urine via organic cation transporters (OCT2, MATE1) in the proximal convoluted tubule. Consequently, total creatinine excreted in urine exceeds filtered creatinine, causing creatinine clearance to overestimate true GFR. As renal disease progresses and GFR drops below $30 ext{ mL/min}$, tubular secretion accounts for an even larger proportion (up to 35%) of total elimination, exaggerating the overestimation of true GFR.
KDIGO guidelines recommend checking Cystatin C (calculating combined eGFRcr-cys) in patients whose creatinine-based eGFR is between $45 ext{ and } 59 ext{ mL/min/1.73 m}^2$ without albuminuria, to confirm or rule out true chronic kidney disease. It is also indicated in patients with atypical muscle mass (bodybuilders, amputees, muscular dystrophy, or neuromuscular paraplegia) where creatinine produces misleading values.
Glomerular hyperfiltration (defined as eGFR $> 130 ext{ to } 140 ext{ mL/min/1.73 m}^2$) is an early pathological hallmark of diabetic nephropathy, obesity-related glomerulopathy, and high-protein intake. Elevated intraglomerular capillary hydrostatic pressure causes hemodynamic barotrauma and podocyte detachment, initiating progressive glomerulosclerosis that precedes overt kidney failure.